| | | | By order of the board of directors, | |
| | | | /s/ WILLIAM R. HINSHAW, JR. William R. Hinshaw, Jr. | |
| | | | President and Chief Executive Officer | |
| | | Page | | |||
| | | | 2 | | | |
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | |
Name | | | Positions and Offices Held with Axcella | | | Director Since | | | Age | |
Gary Pisano, Ph.D. | | | Director | | | 2011 | | | 59 | |
Grégory Behar | | | Director | | | 2016 | | | 51 | |
Cristina M. Rondinone, Ph.D. | | | Director | | | 2018 | | | 60 | |
Shreeram Aradhye, M.D. | | | Director | | | 2020 | | | 58 | |
Name | | | Positions and Offices Held with Axcella | | | Director Since | | | Age | |
William R. Hinshaw, Jr. | | | Director, Chief Executive Officer | | | 2018 | | | 53 | |
Martin Hendrix, Ph.D. | | | Director | | | — | | | 54 | |
Catherine Angell Sohn, Pharm.D. | | | Director | | | 2019 | | | 69 | |
Name | | | Positions and Offices Held with Axcella | | | Director Since | | | Class and Year in Which Term Will Expire | | | Age | |
David R. Epstein | | | Director | | | 2017 | | | Class I – 2023 | | | 59 | |
William D. Baird III | | | Director | | | 2018 | | | Class I – 2023 | | | 49 | |
William Hinshaw | | | Director, Chief Executive Officer | | | 2018 | | | Class III – 2022 | | | 52 | |
Stephen Hoge, M.D. | | | Director | | | 2014 | | | Class III – 2022 | | | 45 | |
Catherine A. Sohn, PharmD. | | | Director | | | 2019 | | | Class III – 2022 | | | 68 | |
Name | | | Position and Offices Held with Axcella | | | Director Since | | | Class and Year in Which Term Will Expire | | | Age | |
David R. Epstein | | | Director | | | 2017 | | | Class I – 2023 | | | 60 | |
William D. “Chip” Baird | | | Director | | | 2018 | | | Class I – 2023 | | | 50 | |
Gary P. Pisano, Ph.D. | | | Director | | | 2011 | | | Class II – 2024 | | | 60 | |
Cristina M. Rondinone, Ph.D. | | | Director | | | 2018 | | | Class II – 2024 | | | 61 | |
Shreeram Aradhye, M.D. | | | Director | | | 2020 | | | Class II – 2024 | | | 59 | |
Name | | | Position Held with Axcella | | | Officer Since | | | Age | |
Manu Chakravarthy, M.D., Ph.D.(1) | | | Executive Vice President of Clinical Development, Chief Medical Officer | | | 2017 | | | 47 | |
Paul Fehlner, J.D., Ph.D. | | | Senior Vice President, Chief Legal Officer and Corporate Secretary | | | 2018 | | | 57 | |
Laurent Chardonnet | | | Senior Vice President, Chief Financial Officer | | | 2019 | | | 56 | |
Alison Schecter, M.D.(1) | | | President of Research and Development | | | 2021 | | | 57 | |
Name | | | Position Held with Axcella | | | Officer Since | | | Age | |
Paul Fehlner, J.D., Ph.D. | | | Senior Vice President, Chief Legal Officer and Corporate Secretary | | | 2018 | | | 58 | |
Alison Schecter, M.D. | | | President of Research and Development | | | 2021 | | | 58 | |
Margaret James Koziel, M.D. | | | Senior Vice President and Chief Medical Officer | | | 2021 | | | 62 | |
Virginia R. Dean | | | Senior Vice President, Chief People Officer | | | 2021 | | | 56 | |
Robert Crane | | | Senior Vice President, Chief Financial Officer | | | 2022 | | | 63 | |
| | | 2020 | | | 2019 | | ||||||
Audit fees(1) | | | | $ | 380,320 | | | | | $ | 355,250 | | |
Audit-related fees(2) | | | | | 205,461 | | | | | | 436,424 | | |
Tax fees | | | | | — | | | | | | — | | |
All other fees(3) | | | | | 1,895 | | | | | | 1,895 | | |
Total fees | | | | $ | 587,676 | | | | | $ | 793,569 | | |
Fee Category | | | Fiscal Year 2021 ($) | | | Fiscal Year 2020 ($) | | ||||||
Audit and audit-related fees(1) | | | | $ | 588,307 | | | | | $ | 627,676 | | |
Tax fees | | | | | — | | | | | | — | | |
All other fees | | | | | — | | | | | | — | | |
Total Fees | | | | $ | 588,307 | | | | | $ | 627,676 | | |
Director | | | S. Aradhye(2) | | | W. Baird(1) | | | D. Epstein(2) | | | W. Hinshaw(2) | | | M. Hendrix | | | G. Pisano | | | C. Rondinone | | | C. Sohn | | | ||
Class | | | II | | | I | | | I | | | III | | | III | | | II | | | II | | | III | | | ||
Committees | | |||||||||||||||||||||||||||
Audit | | | | | | Chair | | | | | | | | | | | | X | | | | | | | | | ||
Compensation | | | | | | X | | | | | | | | | | | | | | | | | | Chair | | | ||
Nominating & Corporate Governance | | | | | | | | | | | | | | | | | | | | | X | | | Chair | | | ||
Skills & Experience | | |||||||||||||||||||||||||||
Business Development | | | | | | X | | | X | | | X | | | X | | | | | | X | | | X | | | ||
CEO Experience | | | | | | | | | X | | | X | | | | | | | | | | | | | | | ||
Commercialization | | | X | | | | | | X | | | X | | | X | | | | | | | | | X | | | ||
Digital | | | | | | | | | X | | | | | | | | | | | | | | | | | | ||
Drug Development | | | X | | | | | | X | | | X | | | X | | | | | | X | | | | | | ||
Finance/ Accounting | | | | | | X | | | X | | | X | | | X | | | X | | | | | | | | | ||
Government/ Regulatory | | | X | | | | | | X | | | X | | | | | | | | | | | | X | | | ||
Healthcare Industry | | | X | | | X | | | X | | | X | | | X | | | | | | X | | | X | | | ||
Human Relations | | | | | | | | | X | | | X | | | | | | | | | X | | | X | | | ||
International | | | X | | | | | | X | | | X | | | X | | | | | | X | | | X | | | ||
Investor Relations | | | | | | X | | | X | | | X | | | | | | | | | | | | X | | | ||
Manufacturing | | | | | | | | | X | | | | | | | | | | | | | | | | | | ||
Science/ Technology | | | X | | | | | | X | | | X | | | X | | | | | | X | | | X | | | ||
Strategy | | | | | | X | | | X | | | X | | | X | | | X | | | X | | | X | | | ||
Treating Physician | | | X | | | | | | | | | | | | | | | | | | | | | | | |
Board Diversity Matrix (As of April 4, 2022) | | ||||||||||||
Total Number of Directors | | | 9 | | |||||||||
| | | Female | | | Male | | | Non- Binary | | | Did Not Disclose Gender | |
Part I: Gender Identity | | | | | | | | | | | | | |
Directors | | | 2 | | | 7 | | | | | | | |
Part II: Demographic Background | | | | | | | | | | | | | |
African American or Black | | | | | | | | | | | | | |
Alaskan Native or Native American | | | | | | | | | | | | | |
Asian | | | | | | 1 | | | | | | | |
Hispanic or Latinx | | | 1 | | | | | | | | | | |
Native Hawaiian or Pacific Islander | | | | | | | | | | | | | |
White | | | 1 | | | 6 | | | | | | | |
Two or More Races or Ethnicities | | | | | | | | | | | | | |
LGBTQ+ | | | | | | | | | | | | | |
Did Not Disclose Demographic Background | | | | | | | | | | | | | |
Name | | Fees Paid In Cash ($) | | Option Awards ($)(1) | | All Other Compensation ($) | | Total ($) | | | Fees Earned or Paid in Cash ($) | | Option Awards ($)(1) | | Restricted Stock Units ($)(1) | | All Other Compensation ($) | | Total ($) | | ||||||||||||||||||||||||||||||||||||
Shreeram Aradhye, M.D. | | | | 11,667 | | | | | 69,335 | | | | | 314,858(2) | | | | | 395,860 | | | | | | 38,750 | | | | | 48,643 | | | | | | | | | | | | | | | 87,393 | | | |||||||||
William D. Baird III | | | | 62,500 | | | | | 28,891 | | | | | — | | | | | 91,391 | | | |||||||||||||||||||||||||||||||||||
William D. “Chip” Baird | | | | 66,250 | | | | | 48,643 | | | | | | | | | | | | | | | 114,893 | | | ||||||||||||||||||||||||||||||
Grégory Behar | | | | 42,500 | | | | | 28,891 | | | | | — | | | | | 71,391 | | | | | | 46,250 | | | | | 48,643 | | | | | | | | | | | | | | | 94,893 | | | |||||||||
David R. Epstein | | | | 150,000(3) | | | | | 275,747 | | | | | 300,000(4) | | | | | 725,747 | | | | | | 153,336(2) | | | | | 485,295 | | | | | 100,000 | | | | | 75,000(3) | | | | | 813,631 | | | |||||||||
Stephen Hoge, M.D. | | | | 45,852 | | | | | 28,891 | | | | | — | | | | | 74,743 | | | | | | 53,750 | | | | | 48,643 | | | | | | | | | | | | | | | 102,393 | | | |||||||||
Gary Pisano, Ph.D. | | | | 42,500 | | | | | 28,891 | | | | | — | | | | | 71,391 | | | |||||||||||||||||||||||||||||||||||
Gary P. Pisano, Ph.D. | | | | 46,250 | | | | | 48,643 | | | | | | | | | | | | | | | 94,893 | | | ||||||||||||||||||||||||||||||
Cristina M. Rondinone, Ph.D. | | | | 39,000 | | | | | 28,891 | | | | | — | | | | | 67,891 | | | | | | 42,750 | | | | | 48,643 | | | | | | | | | | | | | | | 91,393 | | | |||||||||
Catherine A. Sohn, PharmD. | | | | 47,750 | | | | | 28,891 | | | | | — | | | | | 76,641 | | | |||||||||||||||||||||||||||||||||||
Catherine Angell Sohn, Pharm.D. | | | | 57,000 | | | | | 48,643 | | | | | | | | | | | | | | | 105,643 | | |
| | Option Awards(1) | | | Option Awards(1) | | ||||||||||||||||||||
Directors | | Exercisable (#) | | Unexercisable (#) | | |||||||||||||||||||||
Name | | Exercisable (#) | | Unexercisable (#) | | |||||||||||||||||||||
Shreeram Aradhye, M.D. | | | | 1,833 | | | | | 20,167 | | | | | | 9,167 | | | | | 32,833 | | | ||||
William D. Baird III | | | | 42,891 | | | | | 30,140 | | | |||||||||||||||
William D. “Chip” Baird | | | | 66,647 | | | | | 26,384 | | | |||||||||||||||
Grégory Behar | | | | 11,000 | | | | | 11,000 | | | | | | 22,000 | | | | | 20,000 | | | ||||
David R. Epstein(2) | | | | 771,682 | | | | | 228,764 | | | | | | 1,090,446 | | | | | 30,000 | | | ||||
Stephen Hoge, M.D. | | | | 65,288 | | | | | 11,000 | | | | | | 76,288 | | | | | 20,000 | | | ||||
Gary Pisano, Ph.D. | | | | 92,433 | | | | | 11,000 | | | |||||||||||||||
Gary P. Pisano, Ph.D. | | | | 22,000 | | | | | 20,000 | | | |||||||||||||||
Cristina M. Rondinone, Ph.D. | | | | 39,834 | | | | | 28,310 | | | | | | 62,366 | | | | | 25,778 | | | ||||
Catherine A. Sohn, PharmD. | | | | 9,165 | | | | | 23,835 | | | |||||||||||||||
Catherine Angell Sohn, Pharm.D. | | | | 27,497 | | | | | 25,503 | | |
| | Annual Retainer | | | Annual Retainer | | ||||||||
Board of Directors: | | | | | | | | | | | | | ||
All non-employee members, except chairman | | | $ | 35,000 | | | | | $ | 40,000 | | | ||
Audit Committee: | | | | | | | | | | | | | ||
Members | | | $ | 7,500 | | | | | $ | 7,500 | | | ||
Chairman | | | $ | 15,000 | | | | | $ | 15,000 | | | ||
Compensation Committee: | | | | | | | | | | | | | ||
Members | | | $ | 5,000 | | | | | $ | 5,000 | | | ||
Chairman | | | $ | 10,000 | | | | | $ | 10,000 | | | ||
Nominating and Corporate Governance Committee: | | | | | | | | | | | | | ||
Members | | | $ | 4,000 | | | | | $ | 4,000 | | | ||
Chairman | | | $ | 8,000 | | | | | $ | 8,000 | | |
| | Equity Compensation Plan Information | | |||||||||||||||||||||||||||||||||||
Plan Category | | Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights (#) | | Weighted-average Exercise Price of Outstanding Options, Warrants and Rights ($) | | Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in First Column) (#) | | | Number of securities to be issued upon exercise of outstanding options, warrants and rights | | Weighted average exercise price of outstanding options, warrants and rights | | Number of securities remaining available for future issuance under equity compensation plans (excluding securities in first column) | | ||||||||||||||||||||||||
Equity compensation plans approved by security holders (1) | | | | 5,267,547(2) | | | | $ | 5.95 | | | | | 1,365,174(3)(4) | | | | | | 6,472,638(2) | | | | $ | 5.47 | | | | | 1,649,408(3)(4) | | | ||||||
Equity compensation plans not approved by security holders | | | | — | | | | | — | | | | | — | | | | | | — | | | | | — | | | | | — | | | ||||||
Total | | | | 5,267,547 | | | | $ | 5.95 | | | | | 1,365,174 | | | | | | 6,472,638 | | | | $ | 5.47 | | | | | 1,649,408 | | |
Name | | | Year | | | Salary ($) | | | Bonus ($) | | | Stock Awards ($)(1) | | | Option Awards ($)(1) | | | Non-Equity Incentive Plan Compensation ($)(2) | | | All Other Compensation ($) | | | Total ($) | | ||||||||||||||||||||||||
William Hinshaw President and CEO | | | | | 2020 | | | | | | 517,500 | | | | | | — | | | | | | 703,500 (3) | | | | | | 418,531 | | | | | | 286,000 | | | | | | 8,550(4) | | | | | | 1,934,081 | | |
| | | 2019 | | | | | | 496,731 | | | | | | — | | | | | | — | | | | | | 560,049 | | | | | | 288,750 | | | | | | — | | | | | | 1,345,530 | | | ||
Laurent Chardonnet Senior Vice President and Chief Financial Officer | | | | | 2020 | | | | | | 375,000 | | | | | | — | | | | | | — | | | | | | 55,509(5) | | | | | | 151,875 | | | | | | 49,189(6) | | | | | | 631,573 | | |
| | | 2019 | | | | | | 38,462 | | | | | | — | | | | | | — | | | | | | 160,977(5) | | | | | | — | | | | | | 3,000(7) | | | | | | 202,439 | | | ||
Manu Chakravarthy, M.D., Ph.D.(9) Executive Vice President of Clinical Development, Chief Medical Officer | | | | | 2020 | | | | | | 415,392 | | | | | | 300,000(8) | | | | | | 298,800 | | | | | | — | | | | | | 167,219 | | | | | | 8,550(4) | | | | | | 1,189,961 | | |
| | | 2019 | | | | | | 374,000 | | | | | | — | | | | | | — | | | | | | 1,180,679 | | | | | | 155,210 | | | | | | — | | | | | | 1,709,889 | | |
Name and Principal Position | | | Year | | | Salary ($) | | | Bonus ($) | | | Stock Awards ($) | | | Option Awards ($)(1) | | | Non-Equity Incentive Plan Compensation ($)(2) | | | All Other Compensation ($) | | | Total ($) | | |||||||||||||||||||||
William R. Hinshaw, Jr. President and CEO | | | | | 2021 | | | | | | 546,250 | | | | | | | | | | | | | | | 1,913,241(3) | | | | | | 275,275 | | | | | | 8,700(4) | | | | | | 2,743,466 | | |
| | | 2020 | | | | | | 517,500 | | | | | | | | | 703,500(5) | | | | | | 418,531 | | | | | | 286,000 | | | | | | 8,550(4) | | | | | | 1,934,081 | | | ||
Laurent Chardonnet(6) Senior Vice President and Chief Financial Officer | | | | | 2021 | | | | | | 361,703 | | | | | | | | | 395,400(6) | | | | | | 612,237(6) | | | | | | 0(6) | | | | | | 53,300(7) | | | | | | 1,422,640 | | |
| | | 2020 | | | | | | 375,000 | | | | | | | | | | | | | | | 55,509 | | | | | | 151,875 | | | | | | 49,189(8) | | | | | | 631,573 | | | ||
| | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||
Alison Schecter, M.D. President of Research and Development | | | | | 2021 | | | | | | 357,981 | | | | | | | | | | | | | | | 1,399,075(9) | | | | | | 158,850 | | | | | | 8,700(4) | | | | | | 1,924,606 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Name | | | Target Bonus (% of base salary) | | |||
William R. Hinshaw, Jr. | | | | | 55 | | |
Laurent Chardonnet | | | | | 40 | | |
| | | | 40 | | |
| | | | | | | | | | | | Option awards | | Stock awards | | | Option Awards | | Stock Awards | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Name | | Number of Securities Underlying Unexercised Options Exercisable (#) | | Number of Securities Underlying Unexercised Options Unexercisable (#) | | Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#) | | Option Exercise Price ($) | | Option Expiration Date | | Number of Shares or Units Not Vested (#) | | Market value of shares or units of stock that have not vested ($)(1) | | Equity Incentive Plan Awards: Number of Unearned Share Units or Other Rights That Have Not Vested (#) | | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights that Have not Vested ($)(1) | | | | Number of Securities Underlying Unexercised Options (#) Exercisable | | Number of Securities Underlying Unexercised Options (#) Unexercisable | | Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#) | | Option Exercise Price ($) | | Option Expiration Date | | Number of Shares or Units of Stock that have not Vested (#) | | Market Value of Shares or Units of Stock that have not Vested ($)(1) | | Equity Incentive Plan Awards: Number of Unearned Share Units or Other Rights That Have Not Vested (#) | | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights that Have not Vested ($)(1) | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
William Hinshaw President and CEO | | | | | 645,580(2) | | | | | 293,448(2) | | | | | — | | | | | 6.21 | | | 6/21/2028 | | | | 50,000(5) | | | | | 259,500 | | | | | — | | | | | — | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 26,600(3) | | | | | 34,200(3) | | | | | — | | | | | 13.83 | | | 3/22/2029 | | | | — | | | | | — | | | | | 150,000(6) | | | | | 778,500 | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | —(4) | | | | | 156,700(4) | | | | | — | | | | | 4.12 | | | 1/2/2030 | | | | — | | | | | — | | | | | — | | | | | — | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
William R. Hinshaw, Jr. President and CEO | | | | | 880,336(2) | | | | | 58,692(2) | | | | | 0 | | | | | 6.21 | | | | | 6/21/2028 | | | | | 50,000(6) | | | | | 104,500 | | | | | 0 | | | | | 0 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 41,800(3) | | | | | 19,000(3) | | | | | 0 | | | | | 13.83 | | | | | 3/22/2029 | | | | | 0 | | | | | | | | | | 150,000(7) | | | | | 313,500 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 78,350(4) | | | | | 78,350(4) | | | | | 0 | | | | | 4.12 | | | | | 1/2/2030 | | | | | 0 | | | | | | | | | | 0 | | | | | 0 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 0(5) | | | | | 375,000(5) | | | | | 0 | | | | | 6.59 | | | | | 2/8/2031 | | | | | 0 | | | | | | | | | | 0 | | | | | 0 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Laurent Chardonnet Senior Vice President and Chief Financial Officer | | | | | 18,125(7) | | | | | 54,375(7) | | | | | — | | | | | 3.40 | | | 12/18/2029 | | | | — | | | | | — | | | | | — | | | | | — | | | | | | | | 47,344(8) | | | | | 0(8) | | | | | 0 | | | | | 3.40 | | | | | 5/27/2022 | | | | | 0 | | | | | 0 | | | | | 0 | | | | | 0 | | | ||||||||||||||||||
| | | 6,250(8) | | | | | 18,750(8) | | | | | — | | | | | 3.40 | | | 12/18/2029 | | | | — | | | | | — | | | | | — | | | | | — | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | — | | | | | — | | | | | 25,000(9) | | | | | 3.40 | | | 12/18/2029 | | | | — | | | | | — | | | | | — | | | | | — | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Manu Chakravarthy, M.D., Ph.D. (13) Executive Vice President of Clinical Development, Chief Medical Officer | | | | | 161,030(10) | | | | | 23,013(10) | | | | | — | | | | | 6.52 | | | 8/9/2027 | | | | 60,000(12) | | | | | 311,400 | | | | | — | | | | | — | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 58,899(11) | | | | | 58,907(11) | | | | | — | | | | | 13.83 | | | 3/11/2029 | | | | — | | | | | — | | | | | — | | | | | — | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 10,250(7) | | | | | 30,750(7) | | | | | — | | | | | 3.40 | | | 12/18/2029 | | | | — | | | | | — | | | | | — | | | | | — | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Alison Schecter, M.D. President of Research and Development | | | | | 0(9) | | | | | 250,000(9) | | | | | 0 | | | | | 5.57 | | | | | 3/17/2031 | | | | | 0 | | | | | 0 | | | | | 0 | | | | | 0 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 25,000(9) | | | | | 50,000(9) | | | | | 0 | | | | | 5.57 | | | | | 3/17/2031 | | | | | 0 | | | | | 0 | | | | | 0 | | | | | 0 | | |
| | | Shares beneficially owned | | |||||||||
Name of Beneficial Owner | | | Number | | | Percentage | | ||||||
5% Stockholders: | | | | | | | | | | | | | |
Flagship Pioneering(1) | | | | | 12,548,414 | | | | | | 33.3% | | |
FMR LLC(2) | | | | | 5,631,132 | | | | | | 14.9% | | |
Nestlé S.A.(3) | | | | | 4,305,541 | | | | | | 11.4% | | |
HarbourVest Partners, LLC(4) | | | | | 2,807,981 | | | | | | 7.5% | | |
Named executive officers and directors: | | | | | | | | | | | | | |
William Hinshaw(5) | | | | | 783,638 | | | | | | 2.1% | | |
Manu Chakravarthy, M.D., Ph.D.(6) | | | | | 271,707 | | | | | | * | | |
Laurent Chardonnet(7) | | | | | 41,422 | | | | | | * | | |
David R. Epstein(8) | | | | | 994,870 | | | | | | 2.6% | | |
Gary Pisano, Ph.D.(9) | | | | | 103,433 | | | | | | * | | |
Stephen Hoge, M.D.(10) | | | | | 76,288 | | | | | | * | | |
William D. Baird III(11) | | | | | 57,080 | | | | | | * | | |
Cristina M. Rondinone, Ph.D.(12) | | | | | 53,717 | | | | | | * | | |
Catherine A. Sohn, PharmD.(13) | | | | | 24,831 | | | | | | * | | |
Grégory Behar, M.B.A.(14) | | | | | 22,000 | | | | | | * | | |
Shreeram Aradhye, M.D.(15) | | | | | 3,667 | | | | | | * | | |
All executive officers and directors as a group (13 persons)(16) | | | | | 2,511,647 | | | | | | 6.7% | | |
Name of Beneficial Owner | | | Shares Beneficially Owned | | | Percentage of Shares Beneficially Owned | | ||||||
5% or Greater Stockholders: | | �� | | | | | | | | | | | |
Flagship Pioneering(1) | | | | | 18,867,785 | | | | | | 35.9% | | |
FMR LLC(2) | | | | | 7,800,835 | | | | | | 14.8% | | |
Nestlé S.A.(3) | | | | | 7,446,902 | | | | | | 14.2% | | |
HarbourVest Partners, LLC(4) | | | | | 4,378,661 | | | | | | 8.3% | | |
Directors, Named Executive Officers and Other Executive Officers | | | | | | | | | | | | | |
William R. Hinshaw, Jr.(5) | | | | | 1,237,972 | | | | | | 2.4% | | |
Alison Schecter, M.D.(6) | | | | | 112,500 | | | | | | * | | |
David R. Epstein(7) | | | | | 1,283,143 | | | | | | 2.4% | | |
Gary P. Pisano, Ph.D.(8) | | | | | 123,433 | | | | | | * | | |
Stephen Hoge, M.D.(9) | | | | | 96,288 | | | | | | * | | |
William D. “Chip” Baird(10) | | | | | 89,836 | | | | | | * | | |
Cristina M. Rondinone, Ph.D.(11) | | | | | 85,249 | | | | | | * | | |
Catherine Angell Sohn, Pharm.D.(12) | | | | | 52,163 | | | | | | * | | |
Grégory Behar, M.B.A.(13) | | | | | 42,000 | | | | | | * | | |
Shreeram Aradhye, M.D.(14) | | | | | 31,000 | | | | | | * | | |
All executive officers and directors as a group (13 persons)(15) | | | | | 3,401,262 | | | | | | 6.5% | | |